MCM
DNA icon

MAI Capital Management’s Ginkgo Bioworks DNA Stock Holding History

MAI Capital Management’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$583 Buy
95
+89
+1,483% +$740 ﹤0.01% 4364
2025
Q4 		$50 Buy
+6
New +$65 ﹤0.01% 4237

Other funds holding DNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MAI Capital Management's DNA Position: Q1 2026 in Review

MAI Capital Management increased its Ginkgo Bioworks (DNA) stake by 1,483% in Q1 2026, buying an estimated $740 and bringing the position to 95 shares worth $583. The position accounts for ﹤0.01% of the portfolio, ranked #4364.

MAI Capital Management first reported a position in DNA in Q4 2025 and has held it in 2 quarters since. 174 funds tracked by Wall St. Rank hold DNA as of Q1 2026.

  • MAI Capital Management held 95 shares of Ginkgo Bioworks worth $583 as of Q1 2026.
  • MAI Capital Management bought 89 Ginkgo Bioworks shares in Q1 2026, an estimated $740.
  • Ginkgo Bioworks made up ﹤0.01% of MAI Capital Management's portfolio in Q1 2026, its #4364 holding.
  • MAI Capital Management first reported a position in Ginkgo Bioworks in Q4 2025 and has held it in 2 quarters since.
  • 174 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2026.

Based on MAI Capital Management's 13F filing for Q1 2026, filed 15 May 2026.